Alfa Cytology offers a cutting-edge service in the development of therapeutic polyclonal antibodies (pAbs) for pancreatic cancer research. Utilizing extensive expertise in basic pancreatic cancer research, we aim to support the scientific community in the discovery of new therapeutics.
Overview of Therapeutic Polyclonal Antibody for Pancreatic Cancer
Therapeutic polyclonal antibodies are a heterogeneous mixture of immunoglobulin molecules secreted by different B cell clones in response to an antigen. The preparation of polyclonal antibodies involves several steps, including the selection of a suitable antigen, immunization of host animals (commonly rabbits, goats, or sheep), collection of serum, and purification of the antibodies from the serum. The application of polyclonal antibodies in pancreatic cancer research is multifaceted. They can be used to identify and validate novel biomarkers, study the mechanisms of tumor growth and metastasis, and evaluate the efficacy of potential therapeutic compounds.
Fig. 1 Schematic representation of a) polyclonal and b) monoclonal antibodies. A: antigen; EP: epitope. (Vázquez-Gutiérrez J L, et al, 2015)
In therapies against pancreatic cancer, therapeutic polyclonal antibodies offer the following distinct advantages over monoclonal antibodies:
- Broad Epitope Recognition
- High Affinity and Avidity
- Robustness to Antigenic Variation
- Cost-Effective Production
- Enhanced Signal
- Greater Flexibility in Use
Our Services
Alfa Cytology's services involve a complete development pipeline from antigen design and immunization to antibody purification and characterization. We are committed to providing researchers with reliable and specific therapeutic polyclonal antibody development services to aid in preclinical research and therapy development for pancreatic cancer.
Host Species Selection
Selecting the appropriate host species is crucial for the successful generation of polyclonal antibodies. We offer a variety of competitively priced program packages for different hosts to meet unique needs, including but not limited to the following.
Rabbits |
Mice |
Guinea pigs |
Rats |
Swine |
Sheep |
Canines |
Ferrets |
Available Antigens
- Recombinant Proteins: Recombinant proteins corresponding to pancreatic cancer-related targets are available for immunization and antibody production.
- Synthetic Peptides: Custom-designed synthetic peptides, representing specific epitopes of target proteins, are offered for generating epitope-specific polyclonal antibodies.
- Full-Length Proteins: Full-length proteins ensure the production of antibodies that recognize multiple epitopes on the target antigen.
- Fusion Proteins: Fusion proteins, combining parts of different proteins, are available to generate antibodies against multifunctional targets.
Antibody Purification Methods
Our laboratory offers the following antibody purification methods to ensure the production of high-purity polyclonal antibodies.
- Affinity Chromatography: This method uses antigen-affinity columns to selectively bind and purify antibodies specific to the target antigen, resulting in high-purity antibodies.
- Protein A/G Purification: Protein A or G columns bind the Fc region of antibodies, facilitating the purification of IgG antibodies from serum.
- Ion Exchange Chromatography: This technique separates antibodies based on their charge, enhancing the purity and specificity of the final product.
- Size Exclusion Chromatography: Size exclusion chromatography separates antibodies based on their molecular size, removing any contaminants and aggregates from the antibody preparation.
Alfa Cytology is a solution provider dedicated to helping our clients meet the key challenges encountered in the field of pancreatic cancer research. We offer a full suite of custom polyclonal antibody services against a variety of antigens, and based on your application needs for these antibodies, our scientists will design custom immunization, screening, and purification strategies. Please contact us for more information.
Reference
- Vázquez-Gutiérrez J L, Langton M. Current potential and limitations of immunolabeling in cereal grain research. Trends in Food Science & Technology. 2015, 41(2): 105-117.
